Health & TechBethesda, Maryland
An early T-cell trial stalled tumors in patients whose cancers had resisted immunotherapy
In an NIH-led phase 1/2 trial published in Nature Medicine, invikafusp alfa stopped progression in 16 of 27 patients at the optimal dose and shrank tumors in four. These are early results, not a cure.
Verified · National Institutes of Health